Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2015-09-22
Target enrollment:
Participant gender:
Summary
Prospective, non-comparative, mono-center pilot study. Patients with neovascular age-related
macular degeneration (nAMD), responding insufficiently to the maximal standard care with
monthly intravitreal anti-VEGF injections are given adjuvant oral mineralocorticoid receptor
antagonists for 4 months and observed for any changes in vision or retinal structure during
the 4 months of adjuvant treatment, plus 2 additional months without adjuvant treatment.